Analysts expect BRAINSWAY LTD/S (NASDAQ:BWAY) to report sales of $5.85 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for BRAINSWAY LTD/S’s earnings. The highest sales estimate is $5.90 million and the lowest is $5.80 million. The business is scheduled to report its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that BRAINSWAY LTD/S will report full year sales of $23.05 million for the current year, with estimates ranging from $22.90 million to $23.20 million. For the next fiscal year, analysts anticipate that the business will report sales of $30.30 million, with estimates ranging from $29.50 million to $31.10 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for BRAINSWAY LTD/S.
BRAINSWAY LTD/S (NASDAQ:BWAY) last announced its earnings results on Monday, August 26th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06). The firm had revenue of $5.70 million for the quarter, compared to analyst estimates of $5.30 million.
Large investors have recently bought and sold shares of the stock. Victory Capital Management Inc. purchased a new position in BRAINSWAY LTD/S in the 2nd quarter valued at $157,000. Noked Capital LTD purchased a new position in BRAINSWAY LTD/S in the 2nd quarter valued at $572,000. ARK Investment Management LLC purchased a new position in BRAINSWAY LTD/S in the 2nd quarter valued at $863,000. Finally, Delek Group Ltd. purchased a new position in BRAINSWAY LTD/S in the 2nd quarter valued at $3,176,000. Hedge funds and other institutional investors own 10.84% of the company’s stock.
Shares of BWAY opened at $10.17 on Tuesday. The business’s 50 day simple moving average is $9.98. BRAINSWAY LTD/S has a 12-month low of $8.00 and a 12-month high of $12.39.
BRAINSWAY LTD/S Company Profile
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.
Recommended Story: LIBOR
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.